5-Fluorouracil/Leucovorin

DRUG3 trials

Sponsors

OSI Pharmaceuticals, Gruppo Oncologico del Nord-Ovest, Sun Yat-sen University

Conditions

Colorectal Cancer MetastaticHepatocellular CarcinomaLocally Advanced or Metastatic Adenoca of the Biliary Tract

Phase 2

A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer

CompletedNCT00088270

OSI PharmaceuticalsLocally Advanced or Metastatic Adenoca of the Biliary Tract

Start: 2004-08-31End: 2005-08-31Target: 58Updated: 2006-02-22

First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer

CompletedNCT01163396

Gruppo Oncologico del Nord-OvestColorectal Cancer Metastatic

Start: 2007-07-31End: 2010-04-30Updated: 2015-03-11

RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2015-04-30End: 2017-04-30Target: 28Updated: 2015-04-27

Related Papers

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.

2016-12-1347 citations

Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies.

Journal of Clinical Oncology2016-05-20

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.

2010-08-09178 citations